© ACCESSWIRE
11.12.2025
MAJI
LISTED
OTC
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
News Preview
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to announce that it has executed a Letter of Intent to acquire a high-growth, established telehealth organization. Once acquired the Telehealth Platform will ope...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
TTNP
LISTED
NASDAQ
Black Titan Introduces DAT+ Collaborative Engagement Pillar to Support High-Value Decentralized Ecosystems
News Preview
NEW YORK, NY / ACCESS Newswire / December 11, 2025 / Black Titan Corporation (NASDAQ:BTTC) announced the fourth pillar of its DAT+ initiative, outlining a framework for structured collaboration with decentralized projects demonstrating technical strength and long-term potential.The Company may consider partnership elements such as:providing insight...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
BYSI
LISTED
NASDAQ
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
News Preview
FLORHAM PARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study (Lancet Resp Med 12:775, 2024), showing that Plinabulin plus docetaxel provide...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
11.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
News Preview
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
11.12.2025
CNTA
LISTED
NASDAQ
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
News Preview
Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
CBUS
LISTED
NASDAQ
Cibus Welcomes the Positive Conclusion of Trilogue Negotiations on New Genomic Techniques Legislation Between the European Parliament and Council
News Preview
Political agreement on New Genomic Techniques (NGTs), including gene editing, advances a science-based path for plant breeding innovation and supports Cibus’ plans to bring improved traits to European growers...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
News Preview
NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study ("C...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
TLRY
LISTED
TSX
Redecan Cannabis Brand Elevates the Diamond Vape Category with the Launch of Amped Live Resin Liquid Diamond Vapes
News Preview
TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage and wellness industries, announces the launch of Amped Live Resin Liquid Diamond 1g 510 cartridges, marking Redecan’s first live resin–liquid diamond...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
IRD
LISTED
NASDAQ
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
News Preview
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ACIU
LISTED
NASDAQ
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
News Preview
The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
9969
LISTED
HKSE
InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
News Preview
In the registrational clinical trial, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile, with ORR of 89.1% and DCR of 96.4%....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
CERT
LISTED
NASDAQ
Certara Appoints Jon Resnick as Chief Executive Officer
News Preview
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
11.12.2025
TTNP
LISTED
NASDAQ
Black Titan Releases DAT+ Earnings Alignment Pillar Highlighting How Token Utility Interfaces With Economic Activity
News Preview
NEW YORK, NY / ACCESS Newswire / December 11, 2025 / Black Titan Corporation (NASDAQ:BTTC) unveiled the third pillar of its DAT+ strategy, focusing on how token utility interacts with the economic structures of decentralized ecosystems.This pillar evaluates how tokens participate in:fee-based revenue loops,usage-driven consumption models,protocol-l...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
TRNR
LISTED
NASDAQ
Interactive Strength Inc. (NASDAQ: TRNR) Secures New $200k+ Wattbike Order From Fitness First in Germany
News Preview
Driven by rollout of the next-generation Wattbike AIR-PRO across Germany's Fitness First's premium Black Label facilitiesMajor order follows April's $1M+ order from Woodway for the US market AUSTIN, TEXAS / ACCESS Newswire / December 11, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of innovativ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC Pink:MDCE) to Launch Apps Through iHeartRadio's Network, Leveraging 270 Million Monthly Listeners
News Preview
MESA, ARIZONA / ACCESS Newswire / December 11, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce a new strategic marketing partnership with iHeartRadio, the leading audio media company in America. This collaboration will harness iHeartRadio's extensive network of radio stations, podcasts, and digital channels to promote M...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
TTNP
LISTED
NASDAQ
Black Titan Outlines DAT+ Risk Management Pillar Focused on Diversification and Institutional Oversight
News Preview
NEW YORK, NY / ACCESS Newswire / December 11, 2025 / Black Titan Corporation (NASDAQ:BTTC) released the second pillar of its DAT+ strategic framework, presenting a structured, institutional approach to risk evaluation and diversified asset assessment.This pillar establishes a disciplined review process that considers:Governance quality and ecosyste...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
SKNY
LISTED
CSE
Lir Life Sciences stellt Design einer vergleichenden Tierstudie zur Beurteilung der über zellpenetrierende Peptide vermittelten Verabreichung von “GLP”/”GIP”-basierten Adipositastherapien fertig
News Preview
Lir Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), Lir oder das Unternehmen, freut sich, das Design einer neuen vergleichenden Studie zur Aufnahme von zellpenetrierenden Peptiden (die Studie) in der “GLP”/”GIP”-basierten Adipositastherapie bekannt zu geben. “GLP” (Glukose-abhängiges insulinotropes Polypeptid) und “GIP” (Glucagon-like Pepti......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
CASI
LISTED
NASDAQ
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
News Preview
- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI, the "Company"), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
TTNP
LISTED
NASDAQ
Black Titan Introduces DAT+ and Releases First Pillar Focused on Utility-Driven Digital Asset Participation
News Preview
NEW YORK, NY / ACCESS Newswire / December 11, 2025 / Black Titan Corporation (NASDAQ:BTTC) today announced the planned introduction of Digital Asset Treasury Plus (DAT+), a comprehensive strategic framework outlining how the Company may evaluate and potentially engage with digital assets going forward. DAT+ is structured as a multi-layered approach...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
41510
LISTED
XJPX
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
News Preview
Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 f...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
950
LISTED
HKSE
Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
News Preview
Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potentialSynergistic and complementary to Lee's Pharm's existing products pipeline, andAcquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCBHONG KONG, Dec. 11, 2025 /PRNewswire/ -- Nova ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
AIML
LISTED
CSE
AIML Announces Engagement of Guerilla Capital for Communications and Investor Outreach Efforts
News Preview
TORONTO, ON / ACCESS Newswire / December 11, 2025 / AI/ML Innovations Inc. (CSE:AIML) ("AIML" or the "Company") is pleased to announce the engagement of Guerilla Capital ("Guerilla"), an arm's length investor relations firm with offices in Ontario, Canada. Guerilla will provide investor relations services to the Compan...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and D
News Preview
STOCKHOLM, Sweden, December 11, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented new preclinical data on its immunotherapy SVF-001, targeting hepatitis B and D, as a late-breaking abstract at the HepDart scientific meeting held December 7-11 in Honolulu, Hawaii. The results are...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
IMAB
LISTED
NASDAQ
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
News Preview
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistanceThe study achieved its objective, as the new Q6W extended dosing interva...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
BIOV
LISTED
XWSX
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
News Preview
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. December 11, 2025, 7am CEST
BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027
Significant value inflection poi......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
1SXP
LISTED
XETR
SCHOTT Pharma erreicht Jahresziele für Umsatz und Profitabilität
News Preview
SCHOTT Pharma erreicht Jahresziele für Umsatz und Profitabilität
Währungsbereinigtes Umsatzwachstum von 5,8 % auf 986,2 Mio. EUR
Währungsbereinigte EBITDA-Marge steigt auf 28,4 % (Vorjahr: 26,9 %)
Anteil margenstarker High Value Solutions (HVS) bei 57 % (Vorjahr: 55 %)
Prognose für 2026: Währungsbereinigtes Umsatzwachstum von 2–5 % und EBITDA-M......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
AFX
LISTED
XETR
Carl Zeiss Meditec schließt das Geschäftsjahr 2024/25 mit solidem Umsatzwachstum und einem leichten Anstieg des EBITA ab
News Preview
Carl Zeiss Meditec schließt das Geschäftsjahr 2024/25 mit solidem Umsatzwachstum und einem leichten Anstieg des EBITA[1] ab
Umsatzwachstum bei Geräten und Verbrauchsmaterialien sowie stärkere Auftragseingänge und Auftragsbestände zum Jahresende
JENA, 11. Dezember 2025
Carl Zeiss Meditec erreichte im Geschäftsjahr 2024/25 einen Umsatz v......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
1SXP
LISTED
XETR
SCHOTT Pharma delivers on full-year revenue and profitability targets
News Preview
SCHOTT Pharma delivers on full-year revenue and profitability targets
Revenue of EUR 986.2m reflects a 5.8% growth at constant currencies
EBITDA margin at constant currencies increased to 28.4% (prior year: 26.9%)
Successful expansion of high-value solutions (HVS) – revenue share increased to 57% (prior year: 55%)
Guidance for FY 2026: 2-5% rev......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
AFX
LISTED
XETR
Carl Zeiss Meditec closes fiscal year 2024/25 with solid growth in revenue and slight increase in EBITA
News Preview
Carl Zeiss Meditec closes fiscal year 2024/25 with solid growth in revenue and slight increase in EBITA[1]
Growth in both equipment and consumables sales, along with stronger order intake and higher order backlogs at year-end
JENA, 11 December 2025
Carl Zeiss Meditec achieved revenue of EUR 2,228 million in fiscal year 2024/25 (prior year:......
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
GMAB
LISTED
CPH
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
News Preview
Media Release...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
IPH
LISTED
EURONEXT
Innate Pharma Releases Its 2026 Financial Calendar
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar:
March 26, 2026: Publication of 2025 financial statements
May 13, 2026: Publication of revenue and cash position for 1Q2026
May 21, 2026: Annual General Shareholders Meeting
September 17, 2026: Publi...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
GALD
LISTED
XWSX
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrol...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
ZOM
LISTED
XASE
Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv
News Preview
The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated movie Merv now available on Prime Video ANN ARBOR, MI / ACCESS Newswire / December 11, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
IMVT
LISTED
NASDAQ
Immunovant Announces Pricing of $550 Million Common Stock Financing
News Preview
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before de...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
BSLN
LISTED
SIX
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
News Preview
Allschwil, Switzerland, December 11, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ZEAL
LISTED
CPH
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
News Preview
Press release – No. 19 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ZEAL
LISTED
CPH
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
News Preview
Press release – No. 18 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
News Preview
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
IBAB
LISTED
EURONEXT
China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation technology to expand its production capacity
News Preview
Louvain-la-Neuve, Belgium, December 11, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with China Gold Irradiation (CGI), the largest high standard irradiation service company in...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ROG
LISTED
SIX
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
News Preview
Basel, 11 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establishes Roche's in-vitro diagnostics (IVD) menu as the broadest available for any automated mass spectrometry platform, including already 39 of the most fr...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ADXN
LISTED
SIX
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
News Preview
Ad Hoc Announcement Pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
9926
LISTED
HKSE
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
News Preview
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment for locally advanced unresectable or metastatic tri...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.12.2025
GENF
LISTED
LSE
Genflow to Attend Healthcare Conference
News Preview
Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference LONDON, UK / ACCESS Newswire / December 11, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P. Morgan Healt...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
News Preview
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
NTRA
LISTED
NASDAQ
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG), today announced initial translational research results from the international randomized Phase III PALLAS study.
Presented today at the San Ant...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
LABS
LISTED
TSX
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
News Preview
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,820 shares of common stock and 7,840 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement P...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
207940
LISTED
KOE
Samsung Biologics recognized as a global leader in water security
News Preview
Company receives the highest Water Security rating in two years into participationRecognized for exceptional leadership in environmental stewardshipINCHEON, South Korea, Dec. 10, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that it has received from t...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
45030
LISTED
XJPX
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
News Preview
- Data reflect new insights and precision oncology advancements in portfolio and pipeline -- Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (GEJ) cancer featured in late-breaking oral presentation -TOKYO, Dec. 10, 2025 /PRNewswire/ -- Aste...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
6492
LISTED
TAI
Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors
News Preview
TAIPEI and SAN DIEGO, Dec. 10, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company developing first-in-class therapies for difficult-to-treat cancers, today announced a clinical supply agreement with BeOne Medicines, a global oncology company. This agreement will supply a global, multi-center Phas...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
INFU
LISTED
XASE
Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026
News Preview
InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that the Centers for Medicare and Medicaid Services (“CMS”) has added two of the electronic infusion pu...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
FTRE
LISTED
NASDAQ
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DURHAM, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“RSUs”) on December 10, 2025, to two newly hired employees. The award consisted of 245,000 RSUs that vest in three equal annual inst...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
CTOR
LISTED
NASDAQ
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
News Preview
CRANFORD, N.J., Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the closing of its previously announced registered direct offering with a single healthcare-focused investor, pric...
Themefolio
Profiler
Peergroup
© Newsfile
10.12.2025
DTC
LISTED
CSE
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
News Preview
Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announ...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
NDSN
LISTED
NASDAQ
Nordson Corporation Reports Record Fourth Quarter and Fiscal Year 2025 Results
News Preview
Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal fourth quarter ended October 31, 2025. Sales were $752 million, a 1% increase compared to the prior year’s fourth quarter sales of $744 million. The increase in fourth quarter 2025 sales included favorable currency translation of 2% and a 1% acquisition impact, which was part...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
ANTM
LISTED
NYSE
Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence
News Preview
The board of directors of Elevance Health (NYSE: ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Dividend Increase
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on February 2, 2026, to stockholders of record at the close of business on January 2, 2026.
This quarterly dividend repres...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
CERS
LISTED
NASDAQ
Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America
News Preview
Cerus Corporation (Nasdaq: CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. BCA member blood centers produce approximately half of the U.S. platelet and cryoprecipitate supply. The agreement covers Cerus’ entire INTERCEPT product line....
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
CYH
LISTED
NYSE
Community Health Systems Appoints Kevin Hammons Chief Executive Officer and Jason Johnson Chief Financial Officer
News Preview
Community Health Systems, Inc. (NYSE: CYH) (the “Company” or “CHS”) announced today that the Company’s Board of Directors has appointed Kevin Hammons to chief executive officer and Jason Johnson to chief financial officer, effective immediately. Hammons and Johnson have been serving in these roles on an interim basis since October 1, 2025. Hammons...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
